Yes, dstock, there is no doubt in my mind that poly-iclic and Keytruda will be used in conjunction with DCVax-L by doctors to create either a cure or a managed disease for GBM to start. But we must be approved alone, not in conjunction with these other drugs that have been tested in clinical trials. This was poiinted out to me by those who know more than I do about drug approvals. If we ever hope to create multiple franchises with other potiential drugs we need to be approved alone. And we will be, IMO. Also, it's my understanding that we can send regulators all RWE of DCVax-L working in clinical trials or compassionat settings with other drugs to strengthen our position for approval. Also, I would like to se MHRA recommend the use of poly-ICLC with DCVax-L to get maximum benefit and longevity, if not a cure, but again I don't know if MHRA actually makes those kinds of recommendations. Personally, I would like to see us get approved for new and recurring GBM. Then I'd like to see MHRA recommend NWBO run a Ph 4 trial for Stage III gliomas, since they were included in the clinial trial with poly-ICLC. Again I'm not sure they would ever do that and I don't know if they would even consider suggesting NWBO add Stage III gliomas until Flaskworks' Eden system is up and running.
Happy New Year, dstock! you've earned a day off!
Bullish
Market Data 
Markets 
AI
